Fig. 1: Study design.

d days, EGFR epidermal growth factor receptor, IV intravenous, N number of patients assigned to treatment, NSCLC non-small cell lung cancer, QD once daily, Q2W once every 2 weeks, TKI tyrosine kinase inhibitor.